Franklin Genomic Advancements ETF
HELX
7 hedge funds and large institutions have $2.48M invested in Franklin Genomic Advancements ETF in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
5.62% less ownership
Funds ownership: 31.67% → 26.05% (-5.6%)
20% less capital invested
Capital invested by funds: $3.11M → $2.48M (-$636K)
30% less funds holding
Funds holding: 10 → 7 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
Miami,
Florida
|
+$436K |
| 2 |
LPL Financial
San Diego,
California
|
+$49.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$455K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$363K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$227K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$11.4K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.54K |
HELX Hedge Fund Activity: Q2 2024 in Review
7 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2024, worth a combined $2.48M — down 20% from $3.11M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of HELX and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was GTS Securities, adding an estimated $436K. The largest seller was Jane Street, exiting entirely with an estimated $455K sold.
- 7 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q2 2024, down from 10 in Q1 2024.
- Funds reported $2.48M of Franklin Genomic Advancements ETF stock for Q2 2024, down 20% quarter-over-quarter.
- 1 fund opened new Franklin Genomic Advancements ETF positions in Q2 2024 and 4 closed out, a net change of -3 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q2 2024 was GTS Securities, an estimated $436K added.
- The largest Franklin Genomic Advancements ETF seller in Q2 2024 was Jane Street, an estimated $455K sold.
Based on aggregated 13F filings for Q2 2024.